Skip to content
Screener

Revolution Medicines, Inc. RVMD Other income, net (Note 6)

Other income, net (Note 6) at other companies

Pfizer logo
PfizerPFE
$3.72B+603%
Merck & Co. logo
Merck & Co.MRK
-$99M-1,514%
Erasca, Inc. logo
Erasca, Inc.ERAS
$22K+129%
Relay Therapeutics, Inc. logo
Relay Therapeutics, Inc.RLAY
$7.12M+10.0%
Syndax Pharmaceuticals logo
Syndax PharmaceuticalsSNDX
-$186K+15.8%
BridgeBio Pharma logo
BridgeBio PharmaBBIO

Other financials

Income statement

See full
Revenue-
Operating income-$505.1M-90.8%
Net income-$644.4M-160%
EPS (diluted)-$3.06-134%

Balance sheet

See full
Cash & equivalents$815.4M+103%
Total debt$154.5M+16.3%
Total equity$2.6B+39.7%
Total assets$4.3B+77.9%

Cash flow

See full
Operating cash flow-$387.3M-74.7%
CapEx$2.3M-69.3%
Free cash flow-$389.6M-70.0%

Valuation

See full
Market cap$42.4B+521%
Enterprise value$41.74B+536%

Profitability

See full
Operating margin-88,031.9%-89,488pp
Net margin-76,423.3%-77,733pp
FCF margin-74,273.9%-75,457pp

Returns & leverage

See full
Return on equity-79.1%+182pp
Debt / equity0.1×0.0×
Current ratio11.4×-0.4×

Where this comes from

Reported directly by Revolution Medicines, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OtherNonoperatingIncomeExpense.

The source filing: Revolution Medicines, Inc.’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 4:10 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-335104
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Interest income35,57922,40455,08747,319
Interest expense(23,781)(867)(35,978)(867)
Change in fair value of warrant liability(151,031)(4,578)(166,819)(2,139)
Other expense, net(6)(32)(123)(42)
Total non-operating income (expense), net(139,239)16,927(147,833)44,271
Loss before income taxes(644,371)(247,787)(1,098,187)(461,203)
Net loss$(644,371)$(247,787)$(1,098,187)$(461,203)
Net loss per share attributable to common stockholders, basic and diluted$(3.06)$(1.31)(5.37)$(2.45)

Item 1. Financial Statements.

FAQ

What is Revolution Medicines, Inc.'s other income, net (note 6)?
Revolution Medicines, Inc. (RVMD) reported other income, net (note 6) of -$6K in Q2 2026.
How has Revolution Medicines, Inc.'s other income, net (note 6) changed year-over-year?
Revolution Medicines, Inc.'s other income, net (note 6) increased by 81.3% year-over-year, from -$32K to -$6K.
What does other income, net (note 6) mean?
This captures miscellaneous financial items that fall outside the scope of core operating activities, such as foreign exchange gains or losses, minor investment income, or non-recurring legal settlements. It serves as a catch-all for peripheral financial events that do not stem from the primary business operations. Investors monitor this to isolate core earnings from transient or incidental financial fluctuations.

Ask your AI about Revolution Medicines, Inc.'s other income, net (note 6).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude